Skip to main content

Altimmune, Inc.

corporate_fare Company Profile

Altimmune, Inc.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed ALT - Latest Insights

ALT
Apr 23, 2026, 9:29 PM EDT
Filing Type: 424B5
Importance Score:
9
Altimmune Finalizes $225M Public Offering at Discount, Significant Dilution Expected
Sentiment: Negative
View Wiseek Article
ALT
Apr 22, 2026, 11:28 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Altimmune Prices $225M Public Offering, Signaling Significant Dilution
Sentiment: Negative
View Wiseek Article
ALT
Apr 22, 2026, 9:15 PM EDT
Filing Type: S-3MEF
Importance Score:
8
Altimmune Increases Shelf Registration Capacity by $65 Million for Future Offerings
Sentiment: Negative
View Wiseek Article
ALT
Apr 22, 2026, 5:24 PM EDT
Filing Type: 424B5
Importance Score:
7
Altimmune Commences Underwritten Public Offering of Stock and Warrants to Fund Pivotal MASH Phase 3 Trial
Sentiment: Neutral
View Wiseek Article
ALT
Apr 22, 2026, 4:19 PM EDT
Source: GlobeNewswire
Importance Score:
8
Altimmune Commences Underwritten Public Offering of Stock and Warrants
Sentiment: Negative
View Wiseek Article
ALT
Apr 16, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Shareholders Approve Doubling of Authorized Shares, Paving Way for Future Capital Raises
Sentiment: Negative
View Wiseek Article
ALT
Mar 17, 2026, 7:05 AM EDT
Filing Type: DEF 14A
Importance Score:
9
Altimmune Seeks Shareholder Approval to Double Authorized Stock, Potentially Enabling Significant Future Dilution
Sentiment: Negative
View Wiseek Article
ALT
Mar 06, 2026, 8:01 AM EST
Filing Type: PRE 14A
Importance Score:
9
Altimmune Seeks Shareholder Approval to Double Authorized Common Stock, Enabling Significant Future Capital Raises
Sentiment: Negative
View Wiseek Article
ALT
Mar 06, 2026, 7:56 AM EST
Filing Type: 10-K
Importance Score:
8
Altimmune Reports Strong Clinical Progress for Pemvidutide and Secures Significant Financing
Sentiment: Positive
View Wiseek Article
ALT
Mar 05, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Altimmune's Pemvidutide Gets FDA Breakthrough Status for MASH, Bolstered by $274M Cash
Sentiment: Positive
View Wiseek Article
ALT
Jan 28, 2026, 5:23 PM EST
Filing Type: 424B5
Importance Score:
8
Altimmune Raises $75M via Dilutive Offering at Significant Discount to Fund Clinical Trials
Sentiment: Negative
View Wiseek Article